179 related articles for article (PubMed ID: 37625115)
1. Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.
Malgulwar PB; Danussi C; Dharmaiah S; Johnson W; Singh A; Rai K; Rao A; Huse JT
Neuro Oncol; 2024 Jan; 26(1):55-67. PubMed ID: 37625115
[TBL] [Abstract][Full Text] [Related]
2. Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.
Malgulwar PB; Danussi C; Dharmaiah S; Johnson WE; Rao A; Huse JT
bioRxiv; 2023 Jan; ():. PubMed ID: 36711727
[TBL] [Abstract][Full Text] [Related]
3. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.
Danussi C; Bose P; Parthasarathy PT; Silberman PC; Van Arnam JS; Vitucci M; Tang OY; Heguy A; Wang Y; Chan TA; Riggins GJ; Sulman EP; Lang FF; Creighton CJ; Deneen B; Miller CR; Picketts DJ; Kannan K; Huse JT
Nat Commun; 2018 Mar; 9(1):1057. PubMed ID: 29535300
[TBL] [Abstract][Full Text] [Related]
4. ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma.
Babikir H; Wang L; Shamardani K; Catalan F; Sudhir S; Aghi MK; Raleigh DR; Phillips JJ; Diaz AA
Genome Biol; 2021 Nov; 22(1):311. PubMed ID: 34763709
[TBL] [Abstract][Full Text] [Related]
5. SIRT2 inhibition as the Achilles' heel of ATRX-deficient gliomas.
Turcan Ş
Neuro Oncol; 2024 Jan; 26(1):68-69. PubMed ID: 37941518
[No Abstract] [Full Text] [Related]
6. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.
Kannan K; Inagaki A; Silber J; Gorovets D; Zhang J; Kastenhuber ER; Heguy A; Petrini JH; Chan TA; Huse JT
Oncotarget; 2012 Oct; 3(10):1194-203. PubMed ID: 23104868
[TBL] [Abstract][Full Text] [Related]
7. ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma.
Hu C; Wang K; Damon C; Fu Y; Ma T; Kratz L; Lal B; Ying M; Xia S; Cahill DP; Jackson CM; Lim M; Laterra J; Li Y
Neuro Oncol; 2022 Jun; 24(6):888-900. PubMed ID: 34951647
[TBL] [Abstract][Full Text] [Related]
8. Global changes in chromatin accessibility and transcription following ATRX inactivation in human cancer cells.
Liang J; Liu H; Li G; Qian J; Gao R; Zhou Y; Wang X
FEBS Lett; 2020 Jan; 594(1):67-78. PubMed ID: 31329278
[TBL] [Abstract][Full Text] [Related]
9. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
[TBL] [Abstract][Full Text] [Related]
10. Mutant ATRX: uncovering a new therapeutic target for glioma.
Haase S; Garcia-Fabiani MB; Carney S; Altshuler D; Núñez FJ; Méndez FM; Núñez F; Lowenstein PR; Castro MG
Expert Opin Ther Targets; 2018 Jul; 22(7):599-613. PubMed ID: 29889582
[TBL] [Abstract][Full Text] [Related]
11. G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma.
Wang Y; Yang J; Wild AT; Wu WH; Shah R; Danussi C; Riggins GJ; Kannan K; Sulman EP; Chan TA; Huse JT
Nat Commun; 2019 Feb; 10(1):943. PubMed ID: 30808951
[TBL] [Abstract][Full Text] [Related]
12. Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas.
Bedics G; Szőke P; Bátai B; Nagy T; Papp G; Kránitz N; Rajnai H; Reiniger L; Bödör C; Scheich B
Sci Rep; 2023 Oct; 13(1):18436. PubMed ID: 37891325
[TBL] [Abstract][Full Text] [Related]
13. Novel insights into the epigenetics of diffuse glioma.
Danussi C; Huse JT
Mol Cell Oncol; 2018; 5(5):e1472055. PubMed ID: 30263940
[TBL] [Abstract][Full Text] [Related]
14. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
15. ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.
Qin T; Mullan B; Ravindran R; Messinger D; Siada R; Cummings JR; Harris M; Muruganand A; Pyaram K; Miklja Z; Reiber M; Garcia T; Tran D; Danussi C; Brosnan-Cashman J; Pratt D; Zhao X; Rehemtulla A; Sartor MA; Venneti S; Meeker AK; Huse JT; Morgan MA; Lowenstein PR; Castro MG; Yadav VN; Koschmann C
Cell Rep; 2022 Jan; 38(2):110216. PubMed ID: 35021084
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
Jain S; Gupta P; Shankar KB; Singh R; Siraj F
J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
[TBL] [Abstract][Full Text] [Related]
17. ATRX, a guardian of chromatin.
Aguilera P; López-Contreras AJ
Trends Genet; 2023 Jun; 39(6):505-519. PubMed ID: 36894374
[TBL] [Abstract][Full Text] [Related]
18. Sirt2 suppresses glioma cell growth through targeting NF-κB-miR-21 axis.
Li Y; Dai D; Lu Q; Fei M; Li M; Wu X
Biochem Biophys Res Commun; 2013 Nov; 441(3):661-7. PubMed ID: 24161395
[TBL] [Abstract][Full Text] [Related]
19. Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.
Hariharan S; Whitfield BT; Pirozzi CJ; Waitkus MS; Brown MC; Bowie ML; Irvin DM; Roso K; Fuller R; Hostettler J; Dharmaiah S; Gibson EA; Briley A; Mangoli A; Fraley C; Shobande M; Stevenson K; Zhang G; Malgulwar PB; Roberts H; Roskoski M; Spasojevic I; Keir ST; He Y; Castro MG; Huse JT; Ashley DM
Nat Commun; 2024 Jan; 15(1):730. PubMed ID: 38272925
[TBL] [Abstract][Full Text] [Related]
20. SIRT2 activity is required for the survival of C6 glioma cells.
He X; Nie H; Hong Y; Sheng C; Xia W; Ying W
Biochem Biophys Res Commun; 2012 Jan; 417(1):468-72. PubMed ID: 22166219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
